Patents Examined by Anne Marie S. Wehbé
-
Patent number: 11957765Abstract: The disclosure pertains to methods and compositions for treating disorders affecting the central nervous system (CNS). These disorders include neurometabolic disorders such as lysosomal storage diseases that affect the central nervous system, e.g., Niemann-Pick A disease. They also include disorders such as Alzheimer's disease. The disclosed methods involve contacting an axonal ending of a neuron with a composition containing high titer AAV carrying a therapeutic transgene so that the AAV vector is axonally transported in a retrograde fashion and transgene product is expressed distally to the administration site.Type: GrantFiled: March 3, 2020Date of Patent: April 16, 2024Assignee: Genzyme CorporationInventors: Marco A. Passini, James Dodge
-
Patent number: 11925174Abstract: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is human, human-like, or humanized. The nucleic acid is provided with a means that renders it resistant to DNA rearrangements and/or somatic hypermutations. In one embodiment, the nucleic acid comprises an expression cassette for the expression of a desired molecule in cells during a certain stage of development in cells developing into mature B cells. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.Type: GrantFiled: January 11, 2018Date of Patent: March 12, 2024Assignee: Merus N.V.Inventors: Ton Logtenberg, Rui Daniel Pinto, Erwin Houtzager
-
Patent number: 11926875Abstract: The present disclosure discloses an in-vitro method for detecting presence of metabolically altered cells. Also, an in-vitro method for detecting presence of quiescent cells has been disclosed. The present disclosure discloses an in-vitro method for detecting and predicting presence of cancer. The present disclosure discloses an in-vitro method for monitoring response to anti-cancer therapy. The present disclosure analyses expression of at least one biomarker of pluripotent stem cell for detecting or predicting or monitoring cancer. A related use of the at least one biomarker of pluripotent stem cell marker along with a method of treatment comprising the in-vitro method of detection or prediction has been disclosed herewith.Type: GrantFiled: August 13, 2020Date of Patent: March 12, 2024Assignee: 23IKIGAI PTE LTDInventors: Vinay Kumar Tripathi, Ashish Tripathi
-
Patent number: 11884932Abstract: Methods and systems for generating MGE precursor cells in vitro as well as compositions of enriched MGE precursor cells are provided. The methods and systems provide efficient production of MGE precursors. The methods and systems disclosed herein provide functional MGE precursors which differentiate into functional GABAergic interneurons.Type: GrantFiled: July 24, 2020Date of Patent: January 30, 2024Assignee: The Regents of the University of CaliforniaInventors: Cory R. Nicholas, John L. Rubenstein, Arnold R. Kriegstein, Arturo Alvarez-Buylla
-
Patent number: 11883431Abstract: Provided is a mammalian T cell modified to express the Phf19 at a level that is higher than the level of Phf19 expressed by a T cell that has not been modified to express Phf19. Provided is a genetically-modified mammalian T cell comprising a genetic expression vector comprising (a) virally-, bacterially-, or both virally- and bacterially-derived genetic sequences and (b) a genetic sequence encoding Phf19, whereby the genetic sequence encoding Phf19 within the vector is expressed within the T cell. Pharmaceutical compositions, methods of treating a disease, and methods of inhibiting the differentiation of T cells by epigenetic reprogramming are also provided.Type: GrantFiled: June 5, 2018Date of Patent: January 30, 2024Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Yun Ji, Luca Gattinoni
-
Patent number: 11882815Abstract: The disclosure, in some aspects, relates to methods and compositions for recombinant adeno-associated virus (rAAV)-mediated delivery of genome editing molecules to a pre-implantation embryo.Type: GrantFiled: June 15, 2017Date of Patent: January 30, 2024Assignee: University of MassachusettsInventors: Jaime Antonio Rivera-Perez, Guangping Gao
-
Patent number: 11866736Abstract: The invention encompasses water-forming NADH and NADPH oxidases and the use of these enzymes to treat mammalian diseases or conditions associated with an elevated NADH/NAD+ ratio or NADPH/NADP+ ratio. Such pathologies include disorders caused by one or more defects in the mitochondrial respiratory chain, glucose metabolism disorders, cancers associated with reductive stress, and aging. The invention also provides a research tool for investigating the effect of exogenous water-forming NADH or NADPH oxidases on the metabolism of a mammalian cell, such as a human cell, and for elucidating the role of respiratory chain proteins in mitochondrial disorders.Type: GrantFiled: August 1, 2016Date of Patent: January 9, 2024Assignee: The General Hospital CorporationInventors: Vamsi Mootha, Denis Titov, Valentin Cracan, Zenon Grabarek
-
Patent number: 11859206Abstract: Provided herein are methods of producing, compositions comprising and uses of oligodendrogenic neural progenitor cells (o-NPCs), made using a combination of PDGFR agonist and thyroxin or a thyroxin analogue. The method includes; obtaining ventralized neural progenitor cells (NPCs), the ventralized NPCs expressing Sox2, Nkx6-1, decreased level of Pax6 compared to unpatterned NPCs, and elevated expression of HoxA4 compared to unpatterned NPCs; culturing the ventralized NPCs for about 12 to about 16 days (days 26-40 of FIG. 7; days 12 to 27 of FIG. 10) in neural expansion media (NEM) supplemented with i) PDGFR agonist for the about 12 to about 16 days and ii) thyroxine or a thyroxine analogue for the latter about 7 to about 9 days, to produce o-NPC expressing Sox2 and Nkx2.2, decreased level of Pax6 and Nkx6.1 compared to ventralized NPCs and elevated level of HoxA4 and Olig2 compared to ventralized NPCs.Type: GrantFiled: July 30, 2018Date of Patent: January 2, 2024Assignee: University Health NetworkInventors: Michael George Fehlings, Mohamad Khazaei
-
Patent number: 11793844Abstract: Provided are an enterovirus D68 (EV-D68) or a modified form thereof, or a nucleic acid molecule comprising a genomic sequence or cDNA sequence of the EV-D68 or a modified form thereof, or a complementary sequence of the genomic sequence or cDNA sequence, or a pharmaceutical composition comprising the EV-D68 or a modified form thereof, or the nucleic acid molecule, and use of the EV-D68 or a modified form thereof, or the nucleic acid molecule in the manufacture of a pharmaceutical composition for treating a tumor.Type: GrantFiled: July 18, 2018Date of Patent: October 24, 2023Assignees: XIAMEN UNIVERSITY, YANG SHENG TANG COMPANY, LTD.Inventors: Tong Cheng, Wei Wang, Junkai Wan, Wenkun Fu, Xiangzhong Ye, Jun Zhang, Ningshao Xia
-
Patent number: 11785924Abstract: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is human, human-like, or humanized. The nucleic acid is provided with a means that renders it resistant to DNA rearrangements and/or somatic hypermutations. In one embodiment, the nucleic acid comprises an expression cassette for the expression of a desired molecule in cells during a certain stage of development in cells developing into mature B cells. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.Type: GrantFiled: January 5, 2018Date of Patent: October 17, 2023Assignee: Merus N.V.Inventors: Ton Logtenberg, Mark Throsby, Robert A. Kramer, Rui Daniel Pinto, Cornelis A. De Kruif, Erwin Houtzager
-
Patent number: 11779619Abstract: The present invention provides an oncolytic virus comprising nucleotide sequence(s) encoding one or more immune checkpoint modulator(s). It also concerns a pharmaceutical composition comprising effective amount of said oncolytic virus and, eventually, a pharmaceutically acceptable vehicle and its use for treating proliferative diseases such as cancers.Type: GrantFiled: December 23, 2019Date of Patent: October 10, 2023Assignee: Transgene SAInventors: Nathalie Silvestre, Michel Geist, Karola Rittner, Jean-Baptiste Marchand, Christine Thioudellet
-
Patent number: 11778993Abstract: The present invention relates to polypeptides and more particularly to Transcription Activator-Like Effector derived proteins that allow to efficiently target and/or process nucleic acids. The present invention also concerns methods to use these proteins. The present invention also relates to vectors, compositions and kits in which RVD domains and Transcription Activator-Like Effector (TALE) proteins of the present invention are used.Type: GrantFiled: March 15, 2013Date of Patent: October 10, 2023Assignee: CELLECTIS, S.A.Inventors: Philippe Duchateau, Alexandre Juillerat, Claudia Bertonati
-
Patent number: 11760987Abstract: In alternative embodiments, provided are compositions, including products of manufacture and kits, and methods, for treating a heart failure in a subject in need thereof comprising administering to the subject an isolated or recombinant nucleic acid, an isolated or recombinant or chimeric polypeptide, or an engineered cell, as provided herein, thereby treating the subject. In alternative embodiments, the administration reduces left ventricular (LV) hypertrophy, increases LV peak pressure development, reduced cAMP production and/or improves LV peak pressure decay in a pressure-overload in the subject. In alternative embodiments, provided are compositions and methods for: treating, ameliorating, or slowing the progress of, or protecting (preventing) an individual or a patient against heart failure; or, reducing LV hypertrophy, increasing LV peak pressure development, and/or improving LV peak pressure decay in a pressure-overload in an individual in need thereof.Type: GrantFiled: September 7, 2018Date of Patent: September 19, 2023Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRSInventors: H. Kirk Hammond, Mei Hua Gao, Ngai Chin Lai
-
Patent number: 11738046Abstract: An ex vivo generated population of tissue-specific alternatively-activated macrophages and methods of making and using such macrophages for treating orthopedic injury are provided.Type: GrantFiled: November 2, 2018Date of Patent: August 29, 2023Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATIONInventors: Peiman Hematti, Connie Chamberlain, Anna Elizabeth Breiner Clements, Ray Vanderby, John A. Kink
-
Patent number: 11718832Abstract: Disclosed are findings that: (a) induced pluripotent stem cells derived from aged donors (A-iPSC) show increased genomic instability, a defect in apoptosis, a defect in glucose metabolism, and a blunted DNA damage response are compared to those derived from young donors (Y-iPSC); and (b) inhibition of excessive glutathione-mediated H2O2 scavenging activity, found to be associated with A-iPSC and in turn inhibiting DNA damage response and apoptosis, substantially rescues these defects and reduces the oncogenic potential of A-iPSC. Supplementation of pluripotency factor ZSCAN10 (shown to be poorly activated in A-iPSC and to act upstream of glutathione involvement), e.g.Type: GrantFiled: October 6, 2015Date of Patent: August 8, 2023Assignee: Memorial Sloan-Kettering Cancer CenterInventors: Kitai Kim, Maria Skamagki, Yildirim Dogan
-
Patent number: 11707056Abstract: The present invention is directed to the concept of sectoring antibody gene segment repertoires in order to enable the development of novel, synthetic antibody chain repertoires not seen in nature. The present invention is also directed to the realisation of the inventors that sectoring can also alter gene segment expression by providing new arrangements of gene segment clusters relative to other gene segments and regulatory elements in transgenic immunoglobulin loci, thereby providing for new synthetic antibody chain sequence repertoires. The invention also relates to gene segment inversion.Type: GrantFiled: March 19, 2014Date of Patent: July 25, 2023Assignee: Kymab LimitedInventors: Allan Bradley, E-Chiang Lee
-
Patent number: 11707487Abstract: The present invention provides EpCAM antibodies with different affinities. The present invention also provides chimeric antigen receptors (CARs) specific to EpCAM. CAR T cells comprising human EpCAM scFv having a low and sufficient affinity to EpCAM can avoid targeting healthy tissues with low EpCAM expression while exhibiting long-term efficacy against tumor tissues with high EpCAM expression. The present invention also relates to an adoptive cell therapy method for treating cancer by administering the CAR-T cells comprising human EpCAM scFv to a subject suffering from cancer, whereby the CAR T cells bind to the cancer cells overexpressing EpCAM and kill the cancer cells.Type: GrantFiled: April 13, 2021Date of Patent: July 25, 2023Assignee: AffyImmune Therapeutics, Inc.Inventors: Huan Yang, Moonsoo Jin, Janusz Puc
-
Patent number: 11696572Abstract: Non-human animal cells and non-human animals comprising a humanized Asgr1 locus and methods of using such non-human animal cells and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized Asgr1 locus express a human ASGR1 protein or an Asgr1 protein, fragments of which are from human ASGR1. Methods are provided for using such non-human animals comprising a humanized Asgr1 locus to assess in vivo efficacy of human-ASGR1-mediated delivery of therapeutic molecules or therapeutic complexes to the liver and to assess the efficacy of therapeutic molecules or therapeutic complexes acting via human-ASGR1-mediated mechanisms.Type: GrantFiled: June 27, 2018Date of Patent: July 11, 2023Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Alexander O. Mujica, Viktoria Gusarova, Cheng Wang, Christos Kyratsous, Terra Potocky, Katherine Cygnar, Joel H. Martin
-
Patent number: 11666040Abstract: Mice, embryos, cells, and tissues having a restricted immunoglobulin heavy chain locus and an ectopic sequence encoding one or more ADAM6 proteins are provided. In various embodiments, mice are described that have humanized endogenous immunoglobulin heavy chain loci and are capable of expressing an ADAM6 protein or ortholog or homolog or functional fragment thereof that is functional in a male mouse. Mice, embryos, cells, and tissues having an immunoglobulin heavy chain locus characterized by a single human VH gene segment, a plurality of human DH gene segments and a plurality of human JH gene segments and capable expressing an ADAM6 protein or ortholog or homolog or functional fragment thereof are also provided.Type: GrantFiled: April 15, 2020Date of Patent: June 6, 2023Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Lynn Macdonald, Sean Stevens, Andrew J. Murphy, Margaret Karow, John McWhirter
-
Patent number: 11660337Abstract: The present invention discloses a combination of vaccine strains for treating, preventing, relieving or controlling Canine Distemper, Canine Parvovirus Enteritis and Canine Infectious Hepatitis, comprising: Canine Distemper virus vaccine strain with the microorganism deposition accession number CGMCC No. 19397, Canine Parvovirus vaccine strain with the microorganism deposition accession number CGMCC No. 19398 and Canine Infectious Hepatitis virus vaccine strain with the microorganism deposition accession number CGMCC No. 19396. The three vaccine strains of the combination of vaccine strains are low in toxicity and good in immunogenicity. The present invention further discloses a live vaccine composition using the above-mentioned combination of vaccine strains as immunogen. The vaccine composition is safe and effective.Type: GrantFiled: October 15, 2021Date of Patent: May 30, 2023Assignee: Liaoning Yikang Biological Corporation LimitedInventors: Fengyan Li, Xiuwei Shu, Bo Wang, Yiping Wang, Wenyou Luo, Shenglei Chen, Yanxia Liu